May 19, 2020
Under the many challenges of COVID-19, it has been immensely more difficult for the Life Sciences industry to engage with, educate, and provide samples to healthcare providers (HCPs) regarding their products. Sales Representatives have been grounded as the procedures for in-office visits have become unclear, limiting their ability to reach practitioners effectively.
In an effort to outline the current measures in place, MedPro’s Data Stewardship team is polling HCP offices in all 50 states to acquire firsthand information regarding the rules of engagement for sales representatives for in-office visits during the crisis.
MedPro can partner with your Sales Operations, Compliance, and Legal teams to acquire the most relevant answers regarding in-office engagements for top sales reps and priority HCPs, gaining a valuable competitive edge. Gain answers to specific questions such as, ‘Are there any specialty limitations for visits?,’ ‘What is the current face mask and protective gear policy?,’ ‘Is there a mandatory temperature reading for visits?,’ and more.
Contact us today to work with our data stewardship team to develop specific questions, call scripts, and target lists to ensure your sales representatives can engage with practitioners effectively and safely.
April 14, 2020
With 2019 reporting to CMS Open Payments (Sunshine Act) now complete, it’s a great time to reflect on how you can improve your current reporting processes for next year. The March 31, 2020 reports presented a number of unique reporting challenges, with CMS rolling out new validation requirements for zip codes, drug names, and National Drug Codes (NDCs).
Additionally, CMS tightened its state licensing data validation. If the state license number submitted had expired prior to the start of the Open Payments program on August 1, 2013, the associated record was rejected. Many internal transparency teams and other Aggregate Spend vendors faced difficulties adapting to these new requirements and filling the gaps in their data needed to comply.
We updated Porzio AggregateSpendID®, our industry-leading end-to-end Aggregate Spend tracking and reporting solution, to identify invalid zip codes so that updates could be made prior to their submission to CMS. We additionally used CMS’ Drug Name and National Drug Code Reference Data as the source for reported drug names to assure alignment with the validation source.
Our Aggregate Spend solution is powered by MedProID®, the Life Sciences industry’s most comprehensive healthcare practitioner (HCP) and healthcare organization (HCO) record database, which includes 20+ years of historical license data. By leveraging this data, our team was able to quickly identify and adapt to new Federal requirements on state licensure expiration and validation across millions of practitioners.
If your internal team or your current transparency vendor faced difficulties this year with the challenges above, MedPro Systems is here to help.
Contact us today to discuss how we can help you with next year’s Open Payments reporting, as well as the state and local reporting deadline approaching on July 1, 2020.
March 31, 2020
As part of the many challenges of COVID-19, sending pharmaceutical sales representatives direct to healthcare practitioners (HCPs) or healthcare organizations (HCOs) is no longer an option. The Life Sciences industry as a whole is switching its focus to remote engagements with HCPs and Direct to Practitioner (DTP) sampling during this time.
With this comes the added challenge of remotely verifying HCP license and address data to ensure compliance with the federal and state regulations, including the temporary measures being adopted by various state licensing boards in response to COVID-19. The need for a solution to automate this compliance process within the tools your organization is using today has never been greater, and MedPro Systems is standing by to help.
Our team is also closely monitoring the state licensing board responses to COVID-19 and the temporary regulation changes they’re enacting. We are actively updating our processes to adapt to these changes, and we are here to answer any questions you may have.
Contact us today, and our team would be happy to discuss how our solutions can fit into your remote HCP and HCO engagement strategies. We can also provide our Case study, on how we are streamlining a Top 5 Pharma’s DTP fulfillment process through automated SLN verification for DSCSA compliance.
March 20, 2020
For the fifth year in a row, MedPro Systems has been honored with SAP Concur's Distinguished Partner Award for Life Sciences!
Our industry-leading MedPro Concur Connect suite of solutions are supporting over 400 Life Sciences companies with accurate HCP data for Aggregate Spend in Concur Expense and Invoice, with seamless integration to our Aggregate Spend reporting solution.
Thank you to our partners at SAP Concur for this award!
For more information on the award, please visit SAP Concur’s official Partner Day Growth and Innovation Awards post.
March 19, 2020
As concerns about the Coronavirus (COVID-19) continue to escalate, we want to assure you that MedPro Systems is committed to maintaining the high level of customer support that you are accustomed to in an uninterrupted fashion.
Along with our commitment to our customers, the safety and well-being of our employees and our community are top priorities for us. We are taking measures to prevent the spread of COVID-19 by virtualizing events and restricting travel. Further, all MedPro employees are fully equipped and continuing normal activities remotely. Customers can expect no change to normal response times. Our goal is to ensure our teams are safe, connected, and supported during these unusual circumstances.
If you have any questions, please contact your Customer Support Specialist or use the Contact Us page of our website.
March 17, 2020
Passed in 2013, the Drug Supply Chain Security Act (DSCSA) was enacted as a measure to protect the prescription drug supply chain in the United States against counterfeit, stolen, contaminated, or otherwise harmful products. Under this legislation, Manufacturers, Wholesale Distributors, Dispensers, Repackagers, and Third-Party Logistics Providers are required to gradually implement the new requirements strengthening the FDA’s ability to track and audit their pharmaceutical supply chain over a 10-year timeline.
The next milestone in DSCSA’s timeline is quickly approaching. On November 27, 2020, the FDA will require all Wholesale Distributors to verify the product identifier upon receipt of returned products before further distribution. This will be followed by the interoperability requirement going into effect in 2023, and the states themselves are also reviewing potential changes to license requirements in the wake of the DSCSA uniform national policy licensing standards for Wholesale Distributors and Third-Party Logistics Providers.
Now is the time to ensure you are meeting the current DSCSA requirements and to plan for the additional obligations ahead. All Life Sciences organizations mentioned are required to confirm that their trading partners are Authorized Trading Partners with an FDA Registration or appropriate state license number.
MedPro’s suite of healthcare license validation solutions is powered by our robust Healthcare Organization (HCO) database, MedProID. The MedProID database will allow you to verify that all of your trading partners are authorized pursuant to the DSCSA.
A Top 10 Pharmaceutical Manufacturer currently utilizes MedPro to verify healthcare license data for over 200,000 product shipments annually for DSCSA compliance.
Our team has been closely following the FDA’s implementation of the DSCSA requirements and their impact on state licenses and registrations. We can provide HCO license information for Manufacturers, Wholesale Distributors, and Dispensers. We also have state license information for those states that distinctly license Repackagers, Third-Party Logistics Providers, and Reverse Distributors. MedPro can provide you with the license type, status, number, and expiration date, as well as the address when provided by the authoritative state source.
Contact us today, and our team would be happy to discuss how MedPro can assist your organization with DSCSA compliance.
March 11, 2020
MedPro Systems is pleased to announce that Chelsea Ott has joined the company as Regulatory & Compliance – Senior Associate to support our growing Life Sciences customer base.
Chelsea has extensive experience with healthcare fraud and abuse regulations and assisting Life Sciences and Healthcare organizations with meeting their compliance obligations. Prior to MedPro Systems, Chelsea served as Assistant General Counsel at a New Jersey health system and Healthcare & Life Sciences Associate at a New York City law firm.
Chelsea earned her U.S. Healthcare Compliance Certification and law degree from Seton Hall Law School and her undergraduate degree from the University of Pennsylvania. Chelsea is a member of the New Jersey and New York bar, the New Jersey State Bar Association, the Healthcare Businesswoman’s Association, and the American Health Lawyers Association.
“Chelsea joining our team is another milestone for our organization, to meet our customers’ requests for regulatory and compliance guidance in support of our industry-leading suite of solutions,” says Bryan Andrews, Director of Sales Operations at MedPro Systems. “By now having an in-house attorney to focus on Aggregate Spend & Transparency, Data Privacy, DSCSA and PDMA regulations, this shows MedPro’s commitment to the industries we service.”
“MedPro’s best of breed approach is revered throughout the industry. I am excited to work with our customers to build upon MedPro’s stellar reputation and holistic solution offerings,” added Chelsea. “By further expanding into the regulatory and compliance space, MedPro can offer increased compliance guidance and benchmarking to better assist our customers with their day-to-day needs and questions.”
About MedPro Systems:
MedPro Systems® is trusted by over 550 Life Sciences customers, including 22 of the Top 25 Pharmaceutical Manufacturers, to solve difficult data challenges in managing, validating, and enriching healthcare practitioner (HCP) and healthcare organization (HCO) attributes.
MedPro’s solutions have helped customers seamlessly meet Aggregate Spend, DSCSA, Ohio TDDD, Prescription Drug Marketing Act (PDMA), and Stark Law requirements through the use of their industry-leading MedProID® suite of solutions.
For more information, please visit: www.medprosystems.com
March 10, 2020
Data stewardship serves a vital role for Life Sciences organizations in operationalizing CRM/MDM healthcare practitioner (HCP) data, to streamline and sync internal processes for compliance, sales and marketing teams.
Data stewardship from MedPro Systems helps bridge the requests of all teams, ensuring seamless capture, validation, and dispute management of HCP records in your database for targeted sales representative engagements.
MedPro’s data stewards are full-time employees based in NJ with expertise in managing HCP license and demographic data to comply with federal and state regulations. If you are currently experiencing challenges with your internal or outsourced data stewardship processes, we can help.
Contact us today, to discuss how MedPro’s data stewardship team can help you get the most out of your CRM/MDM healthcare license data.
February 25, 2020
Signed into law on October 24, 2018, the ‘Fighting the Opioid Epidemic with Sunshine Act' expands the scope of reporting requirements under the Open Payments (Sunshine Act) program to include Advanced Practice Registered Nurses (APRN) and Physician Assistants (PA) in the definition of a Covered Recipient.
Starting on January 1, 2022, Life Sciences organizations will be required to report Aggregate Spend data with APRNs and PAs to the Centers for Medicare and Medicaid Services (CMS) for their Open Payments reporting. This means transparency data capture for the 2021 calendar year must include this data for submission to CMS in 2022.
Including APRNs and PAs as Covered Recipients introduces roughly 450K additional healthcare practitioners (HCPs) with potentially reportable transactions, significantly increasing the scale of Open Payments data capture.
Furthermore, there are over 400 variations of state license credentials for APRNs, and not all APRNs and PAs have NPI numbers, adding complexity to existing license validation processes your organization may have.
MedPro’s suite of healthcare license validation solutions are powered by our 25 million HCP database, including all APRN and PA license data required for capture, and backed by our premier customer service.
Our team has been closely following CMS’ implementation of these new requirements and have developed best practices for Life Sciences organizations to review and update their internal data processes to meet them.
Contact us today, and our team would be happy to share in greater detail the impact of this upcoming expansion to Open Payments, the steps your organization should be taking now to prepare for reporting in 2022, and how MedPro Systems can help.